CASI Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CASI Pharmaceuticals, Inc.
MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.
Perrigo can continue claiming its store brand hypoallergenic infant formula saves customers more than 20% compared to leading name brands while providing similar nutrition to leading brands. But meeting AAP standard doesn’t measure up as equivalent to brands, industry self-regulation group says.
The microbiome therapy won approval for preventing recurrence of Clostridioides difficile infections, but an analyst said the future could be in more targeted approaches.
A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.
- Other Names / Subsidiaries
- EntreMed, Inc.
- Miikana Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.